Meprate safe in liver disease
Reading File
Finding Sources
Searching PubMed
medroxyprogesterone acetate liver disease hepatic
Searching the Web
Meprate medroxyprogesterone acetate safety liver disease contraindication
Reading File
Reading File
I now have comprehensive information to give a thorough answer. Here is the full response:
Meprate (Medroxyprogesterone Acetate) in Liver Disease
Bottom line: Meprate (MPA) is generally CONTRAINDICATED in significant/active liver disease, but the picture is nuanced depending on the severity of hepatic impairment and the formulation used.
Why Liver Disease Matters for MPA
MPA is almost exclusively eliminated via hepatic metabolism - it is metabolized to pregnanediol and glucuronide/sulfate conjugates, which are then excreted in the urine. In patients with advanced liver disease, MPA disposition is significantly altered - specifically, elimination is reduced, leading to drug accumulation. This has been formally demonstrated in pharmacokinetic studies of 14 patients with advanced liver disease, where MPA clearance was significantly impaired. - Provera (MPA) FDA Prescribing Label
MPA is a substrate of CYP 450 3A4. Liver disease can disrupt CYP enzyme activity, further compromising drug metabolism. - Harriet Lane Handbook, 23rd ed.
Contraindication Status
Oral MPA (Meprate tablets) - CONTRAINDICATED in liver disease:
Multiple authoritative sources are consistent:
- FDA prescribing information for Provera (oral MPA) lists "known liver dysfunction or disease" as a contraindication (#6 on the contraindication list).
- Mayo Clinic / formal prescribing guidance states: liver disease - should not be used.
- Harriet Lane Handbook (23rd ed.): "Contraindicated in ... liver disease."
- Harrison's Principles of Internal Medicine (22E, 2025): Lists liver disease among contraindications to oral contraceptive/hormonal use.
- StatPearls (NCBI): "In women with hepatic dysfunction or hepatic diseases, medroxyprogesterone usage is contraindicated. Use should be discontinued in women who experience jaundice or disturbances with liver function."
Nuance: Injectable DMPA vs. Oral MPA
The contraindication picture differs slightly between formulations and severity of liver disease:
| Scenario | Oral MPA (Meprate) | Injectable DMPA (Depo-Provera) |
|---|---|---|
| Active liver disease / hepatitis | Contraindicated | Generally avoid; use with caution |
| Compensated cirrhosis | Contraindicated | Can be considered (progestin-only); PMC evidence suggests progestin-only methods are safer than estrogen-containing ones |
| Decompensated cirrhosis | Contraindicated | Avoid (impaired metabolism, accumulation risk) |
| Hepatocellular adenoma | Contraindicated | Avoid (progestin may stimulate adenoma growth) |
| Budd-Chiari syndrome | Contraindicated | Progestin-only agents are considered safer than estrogen |
A 2024 review on contraception in liver disease notes that progestin-only methods (including DMPA injection) can be safely used in patients with compensated cirrhosis because they avoid estrogen-related risks - but this data is for the injectable form, not necessarily oral MPA tablets.
The WHO Medical Eligibility Criteria historically classified injectable DMPA as category 3 (risks outweigh benefits) in hepatic disease, though earlier WHO guidance (2009) was more permissive.
Hepatotoxic Effects of MPA Itself
Even in patients with normal baseline liver function, MPA can:
- Elevate liver function tests (LFTs)
- Cause cholestatic jaundice (listed as an adverse effect in the Harriet Lane Handbook and FDA label)
- Enlarge hepatic hemangiomas
- Alter prothrombin time and clotting factors VII, VIII, IX, and X
- Alter thyroid function tests and metyrapone test results
If jaundice or liver function disturbance develops during MPA use, the drug must be stopped immediately.
Practical Summary
| Situation | Recommendation |
|---|---|
| Active hepatitis / acute liver disease | Do not use MPA (Meprate) |
| Known chronic liver disease (any severity) | Contraindicated - avoid oral MPA |
| Jaundice develops on MPA | Stop immediately |
| Need for menstrual regulation in a patient with liver disease | Consider non-hormonal alternatives (tranexamic acid, NSAIDs, levonorgestrel-IUS if appropriate) |
| Monitoring if MPA is unavoidable | Frequent LFTs; stop if any liver function disturbance appears |
Key references:
- Harriet Lane Handbook, 23rd ed. - Medroxyprogesterone entry, explicit contraindication in liver disease
- Harrison's Principles of Internal Medicine, 22E (2025) - Liver disease listed as contraindication to hormonal therapy
- Provera FDA Label - Hepatic insufficiency pharmacokinetics and contraindication
- StatPearls - Medroxyprogesterone - Comprehensive hepatic impairment guidance
Which progesterone is safe in liver disease
Finding Sources
Searching the Web
which progesterone progestin safe to use in liver disease WHO medical eligibility
Searching PubMed
progestogen progestin liver disease safety hepatic impairment
Finding Sources
Finding Sources
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC10878548
Reading File
Searching the Web
micronized progesterone vaginal transdermal liver disease safe first pass metabolism
Excellent - I now have comprehensive data from multiple authoritative sources. Here is a detailed answer:
Progestogens in Liver Disease: Which Are Safe?
The key principle is: the route of administration and the specific molecule both matter. Avoiding hepatic first-pass metabolism is the safest strategy.
Framework: Why Most Oral Progestogens Are Problematic
All synthetic progestins (including MPA/Meprate) are primarily metabolized by the liver via CYP450 enzymes. In liver disease:
- Drug clearance is reduced - drug accumulates
- Cholestatic injury is possible (progestins can cause cholestatic jaundice)
- Some progestins convert to estrogenic metabolites, adding estrogen-related risks
U.S. Medical Eligibility Criteria (US-MEC) for Progestogens in Liver Disease
From the Goldman-Cecil Medicine table (Table 220-3) and CDC/WHO MEC:
| Liver Condition | Combined Hormonal Contraceptives | Progestin-Only Pills (POPs) | DMPA Injection | Implant / LNG-IUS |
|---|---|---|---|---|
| Compensated cirrhosis | Category 3 (relative CI) | Category 1 (safe) | Category 2 (generally safe) | Category 1 (safe) |
| Decompensated (severe) cirrhosis | Category 4 (absolute CI) | Category 3 (risks outweigh benefits) | Category 3 | Category 3 |
| Hepatocellular adenoma | Category 4 | Category 3 | Category 3 | Category 3 |
| Hepatocellular carcinoma / hepatoma | Category 4 | Category 3 | Category 3 | Category 3 |
| Viral hepatitis (active/carrier) | Category 1-2 | Category 1 (safe) | Category 1 | Category 1 |
| Budd-Chiari syndrome | Category 4 | Safe (preferred over CHC) | Generally usable | Safe |
Category 1 = no restriction; Category 2 = benefits outweigh risks; Category 3 = risks outweigh benefits; Category 4 = absolute contraindication
The Safest Options, Ranked
1. Micronized Progesterone - Vaginal / Transdermal Route (BEST)
Natural (bioidentical) progesterone given vaginally or transdermally bypasses the liver entirely.
- Vaginal micronized progesterone (e.g., Crinone gel, Utrogestan vaginal) undergoes a "vaginal-uterine first-pass effect" - direct uterine absorption with minimal systemic/hepatic load
- Transdermal progesterone also bypasses hepatic first-pass metabolism
- Structurally identical to endogenous progesterone - no synthetic metabolites
- Less inflammatory to hepatocytes than synthetic progestins
- This is the preferred option for women with liver disease needing progesterone support (e.g., HRT, luteal support)
2. Levonorgestrel-IUS (Mirena, LNG-IUS)
- Acts predominantly locally in the uterus
- Minimal systemic absorption - very low hepatic load
- US-MEC Category 1 for most liver conditions including compensated cirrhosis
- Safe even with hepatocellular adenoma (progestin-only agents are safer than estrogen here)
- Preferred for contraception + menorrhagia in liver disease patients
3. Progestin-Only Pills (POPs) - Norethindrone / Levonorgestrel (Minipill)
- US-MEC Category 1 for most liver conditions (viral hepatitis, compensated cirrhosis, Budd-Chiari)
- Avoid in severe decompensated cirrhosis (Category 3) and liver tumors (Category 3)
- Norethindrone (0.35 mg) and levonorgestrel are the agents used in POPs
- The PMC 2024 review confirms POPs can be safely used regardless of underlying liver condition, including with decompensated cirrhosis
4. Subcutaneous Implant (Etonogestrel - Nexplanon)
- Very low systemic dose, minimal hepatic metabolism required
- US-MEC Category 1 for most liver diseases
- Good long-acting option
5. DMPA Injectable (Depo-Provera) - Use with Caution
- Progestin-only, so avoids estrogen risks
- However, less favored in liver disease patients with cirrhosis because:
- Slightly increased VTE risk (unlike other progestin-only methods)
- Reduces bone mineral density - a concern in cirrhosis patients already at fracture risk
- Not ideal, but not an absolute contraindication in compensated disease
6. Oral Synthetic Progestins (MPA/Norethindrone orally) - Avoid or Use Cautiously
- Subject to full hepatic first-pass metabolism
- Oral MPA (Meprate) is contraindicated in liver disease
- Oral norethindrone has somewhat less hepatotoxic potential than MPA, but still metabolized by the liver
- Avoid in significant hepatic impairment
Dydrogesterone - Special Note
Dydrogesterone (Duphaston) is a synthetic progestogen sometimes considered "safer" than MPA because:
- It does not convert to estrogenic metabolites
- Lower androgenic activity
- However, it is still hepatically metabolized, and the prescribing information still lists liver disease as a caution/contraindication
Its use in liver disease is not well established, and it should still be avoided in significant hepatic impairment.
Practical Summary
| Clinical Need | Preferred Progestogen in Liver Disease |
|---|---|
| Contraception | LNG-IUS (Mirena) or Progestin-only pill (norethindrone/levonorgestrel) |
| Luteal phase support / ART | Vaginal micronized progesterone (e.g., Utrogestan vaginally) |
| HRT (opposing endometrium) | Vaginal or transdermal micronized progesterone |
| Menorrhagia | LNG-IUS (Mirena) |
| Endometriosis | LNG-IUS preferred; avoid oral MPA |
| Severe/decompensated cirrhosis | Avoid all hormonal methods if possible; LNG-IUS if needed |
Key rule: if a progestogen is needed in liver disease, choose non-oral routes (vaginal, transdermal, IUS) and prefer natural/bioidentical progesterone over synthetic progestins wherever possible.
Sources: Goldman-Cecil Medicine (Table 220-3 US-MEC); PMC: Contraception in liver disease (2024); NIH LiverTox - Progestins; CDC US Medical Eligibility Criteria
This is a shared conversation. Sign in to Orris to start your own chat.